Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2013 (2013), Article ID 724082, 5 pages
Clinical Study

Urolastic—A New Bulking Agent for the Treatment of Women with Stress Urinary Incontinence: Outcome of 12 Months Follow Up

1MOCONTI Sp.z o.o Urological Office, Warszawa, Poland
2Department of Urology, IATROS NZOZ, Warszawa, Poland
3Department of Urology, Radboud UMC, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
4Department of Urology, Sohag University Hospital, Egypt

Received 6 November 2013; Revised 5 December 2013; Accepted 5 December 2013

Academic Editor: Walid A. Farhat

Copyright © 2013 Janusz Zajda and Fawzy Farag. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To evaluate the efficacy and safety of the new injectable implant, Urolastic, in women with stress urinary incontinence (SUI) after 12-month followup. Materials and Methods. A prospective, cohort study included adult women with SUI. Patients were treated with Urolastic periurethral injections under local anaesthesia. The injection procedure was repeated after 6 weeks when indicated. Patients were evaluated for efficacy and safety parameters 6 weeks, 3 months, and 12 months after therapy. Results. Twenty women 56 (33–71) years old were included. Thirteen patients (65%) received one injection each (overall average of 2,1 mL); 7 patients (35%) received a second injection. Nineteen patients complete the 12-month followup. The mean Stamey incontinence grade significantly decreased from 1.9 at baseline to 0.4 at 12 months (visit IV) ( ). None of the patients were dry at baseline; 68% of them were dry at 12 months. The mean number of incontinence episodes significantly decreased from 6/day at baseline to 1.6/day at visit IV ( ). Reduction in pad weight went from 20.2 to 7.8 g at one year. The mean I-QoL score significantly increased from 51 at baseline to 76 at visit IV ( ). Six patients (30%) developed minor complications related to the injection procedure. Conclusions. Urolastic is effective and long-standing urethral bulking agent with moderate adverse events.